CTIS2022-502313-28-00招募中1 期
A multicenter randomized, double-blind, placebo-controlled Phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (DPNP) / NEPTUNE-17. - 214221
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 240
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- All
入选标准
- •1. 18-75 years of age inclusive, at the time of signing the informed consent. 2. Type I or Type II diabetes with painful, distal, symmetrical, sensory-motor neuropathy attributed to diabetes, of at least 6 months duration; a. Pain must have begun in bilateral distal lower limbs. b. Pain is not related to underlying infection or trauma. c. Diagnosis confirmed by a positive Douleur Neuropathique 4 [DN4] questionnaire at screening. d. Levels of glycosylated haemoglobin A1c (HbA1c) less than 97 mmol/mol (<11%). 3. On a stable anti-diabetic medication regimen (unchanged dose over the last 30 days for diabetes) prior to screening. Adjustment of insulin dose is acceptable, however, resumption of insulin treatment is not allowed since 30 days prior to screening. 4. No unplanned recent hospitalizations due to noncompliance or uncontrolled diabetes. 5. At screening, a pain score =4 and =9 by the 11-point NRS (0-10) for average daily pain intensity over the past 24 hours. 6. During the run-in period; An average of the average daily pain score of =4 and =9 by the 11-point NRS (0-10). Rescue medication use (if required) must be within the permitted allowance., 7. Documented history of insufficient pain relief from, or inability to tolerate, or contraindication to current standard of care therapy, e.g. antidepressants (tricyclic antidepressants [TCAs], selective serotonin reuptake inhibitors [SSRIs] and serotonin-norepinephrine reuptake inhibitors [SNRIs]) OR antiepileptic (anticonvulsant) drugs. 8. Participant must be willing and able to understand and participate in all scheduled evaluations and to complete all required tests and procedures including the use of patient eDiary. This will be judged by the Investigator during the screening period. 9. BMI within the range of 18 to 40 kg/m2 (inclusive). 10. Male or Female participant; A female participant is eligible to participate if she is not pregnant, not breastfeeding, and at least one of the following conditions applies: Not a woman of childbearing potential (WOCBP). OR • Is a WOCBP and using a contraceptive method that is highly effective, with a failure rate of <1%, as described in Section 10.4 during the study intervention period and for at least 16 weeks after the last dose of study intervention. The Investigator should evaluate potential for contraceptive method failure (e.g. noncompliance, recently initiated) in relationship to the first dose of study intervention. • A WOCBP must have a negative highly sensitive pregnancy test (urine or serum as required by local regulations) within 24 hours before the first dose of study intervention. • Additional requirements for pregnancy testing during and after study intervention are located in protocol. • The Investigator is responsible for review of medical history, menstrual history, and recent sexual activity to decrease the risk for inclusion of a woman with an early undetected pregnancy. 11. Capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the ICF and in this protocol
排除标准
- •1. History of significant medical illness 2. Participant has current painful peripheral neuropathy due to a cause other than diabetes 3. Participant has any lower extremity amputation. 4. Participant has a current or previous foot ulcer within the past 3 months 5. Participants who have complications of diseases that are considered to affect the assessment of diabetic peripheral neuropathic pain. 6. Current immunodeficiency diseases 7. History of recurrent/chronic infections 8. Symptomatic herpes zoster within 3 months prior to screening. 9. Current or previous active Mycobacterium tuberculosis infection regardless of treatment. 10. Evidence of latent tuberculosis (TB) as documented by medical history, examination and TB testing: either a positive (not indeterminate) QuantiFERON TB Gold Plus test or a positive (not indeterminate) T-SPOT test. 11. History of significant allergies to monoclonal antibodies. 12. History, diagnosis, signs or symptoms of any clinically significant psychiatric disorder 13. History or evidence of clinically significant multiple or severe drug allergies, or severe post-treatment hypersensitivity reactions 14. Malignancy • History of malignancy within the last 5 years, except for basal cell or squamous epithelial carcinomas of the skin that have been resected with no evidence of metastatic disease for 3 years. • Breast cancer within the past 10 years., 15. Liver • Alanine Aminotransferase (ALT) >1.5× ULN at screening. • Bilirubin >1.5× ULN at screening (isolated bilirubin >1.5× ULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). 16. Hematological laboratory values at screening • White blood cell (WBC) count <3.0×109/L • Hemoglobin <10.0 g/dL • Platelet count <125×109/L 17. Myocardial infarction or unstable angina, or cerebrovascular event within 6 months prior to screening. 18. Unstable or life-threatening cardiac arrhythmia requiring intervention within 3 months prior to screening. 19. New York Heart Association (NYHA) Class III or IV heart failure. 20. Corrected QT interval according to Fridericia’s formula (QTcF) >450 msec or QTcF >480 msec in participants with bundle branch block, at screening or Day 1 visit. 21. Estimated creatinine clearance <45 mL/min/1.73 m2 at screening 22. Planned surgical procedure over the duration of the study. 23. Major surgery within 3 months prior to first dose of study intervention. 24. Participants with a recurrent or chronic infection 25. Use of any analgesic medication is prohibited 26. Recent immunomodulator use within pre-specified timeframes 27. Received live or live attenuated vaccine(s) use within pre-specified timeframes 28. Use of pain interventions within 4 weeks of screening., 29. Current enrollment or past participation in a clinical study of an Investigational Medicinal Product within the last 30 days or 5 half-lives (whichever is longer) 30. Exposure to more than 4 new IMPs within 12 months prior, or any previous exposure to GSK3858279. 31. Participants who are a family member of the Investigator or any associate, colleague, and employee assisting in the conduct of the study 32. Participants who cannot be contacted by phone in an emergency. 33. Participants who are unlikely to comply with the protocol 34. Positive human immunodeficiency virus (HIV) antibody test. 35. Has a positive test for active hepatitis B virus. 36. Positive hepatitis C antibody test result. 37. Positive hepatitis C RNA test result 38. Active or suspected COVID-19 infecti
研究者
相似试验
招募中
2 期
A placebo-controlled Phase 2 study to evaluate efficacy, safety, tolerability, pharmacokinetics and target engagement of GSK3858279 in adult participants with chronic Diabetic Peripheral Neuropathic Pain (NEPTUNE-17)Chronic diabetic peripheral neuropathic painJPRN-jRCT2031230412Okawa Yasutoshi240
尚未招募
不适用
A multicenter randomized, double-blind, placebo-controlled trial for Sheng-Mai-Yin for improvement of the pulmonary heart function related symptoms of convalescence patients of new coronavirus pneumoniaovel Coronavirus Pneumonia (COVID-19)ITMCTR2000003235Wuhan Hospital Of Traditional Chinese and Western Medicine (Wuhan 1st Hospital)
招募中
1 期
A multicenter randomized, double-blind, placebo-controlled trial for Teng-Fu Jiang-Ya tablets combined with Valsartan/Amlodipine in the Treatment of primary hypertension (grade 2) with liver yang hyperactivity syndromeEssential HypertensionITMCTR2000003098Affiliated Hospital of Shandong University of Traditional Chinese Medicine
进行中（未招募）
1 期
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast CancerPatients with operable HER2-positive primary breast cancerMedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022902-41-ATF. Hoffmann-La Roche Ltd.4,804
进行中（未招募）
1 期
A Study of Pertuzumab in Addition to Chemotherapy and Herceptin (Trastuzumab) as Adjuvant Therapy in Patients With HER2-Positive Primary Breast CancerPatients with operable HER2-positive primary breast cancerMedDRA version: 23.0Level: PTClassification code 10065430Term: HER2 positive breast cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2010-022902-41-SEF. Hoffmann-La Roche Ltd.4,804